Blueprint Medicines Corporation (NASDAQ:BPMC) has been given a consensus recommendation of “Buy” by the ten analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $53.50.

Several analysts have weighed in on BPMC shares. BidaskClub downgraded shares of Blueprint Medicines Corporation from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 19th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $56.00 price objective on shares of Blueprint Medicines Corporation in a report on Tuesday. Canaccord Genuity set a $52.00 price target on shares of Blueprint Medicines Corporation and gave the stock a “buy” rating in a report on Tuesday, June 6th. Cowen and Company reissued a “buy” rating on shares of Blueprint Medicines Corporation in a report on Tuesday, June 6th. Finally, Zacks Investment Research raised shares of Blueprint Medicines Corporation from a “sell” rating to a “hold” rating in a report on Monday, July 17th.

COPYRIGHT VIOLATION WARNING: “Blueprint Medicines Corporation (BPMC) Receives Average Recommendation of “Buy” from Brokerages” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/09/09/blueprint-medicines-corporation-bpmc-receives-average-recommendation-of-buy-from-brokerages.html.

Blueprint Medicines Corporation (NASDAQ BPMC) opened at 52.28 on Friday. The company’s market cap is $2.05 billion. Blueprint Medicines Corporation has a 52 week low of $25.08 and a 52 week high of $56.93. The firm’s 50 day moving average is $50.44 and its 200-day moving average is $44.63.

Blueprint Medicines Corporation (NASDAQ:BPMC) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.75) by $0.11. The firm had revenue of $5.89 million for the quarter, compared to the consensus estimate of $5.96 million. Blueprint Medicines Corporation had a negative return on equity of 45.58% and a negative net margin of 388.91%. The company’s revenue was down 16.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.70) EPS. On average, analysts predict that Blueprint Medicines Corporation will post ($3.59) earnings per share for the current fiscal year.

In other news, insider Kate Haviland sold 6,357 shares of Blueprint Medicines Corporation stock in a transaction on Wednesday, June 28th. The shares were sold at an average price of $50.00, for a total value of $317,850.00. Following the transaction, the insider now directly owns 6,357 shares of the company’s stock, valued at approximately $317,850. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel Lynch sold 32,500 shares of Blueprint Medicines Corporation stock in a transaction on Wednesday, June 28th. The shares were sold at an average price of $50.28, for a total transaction of $1,634,100.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 128,622 shares of company stock worth $6,484,605. 3.40% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the company. Lord Abbett & CO. LLC grew its position in Blueprint Medicines Corporation by 0.5% in the 2nd quarter. Lord Abbett & CO. LLC now owns 1,729,169 shares of the biotechnology company’s stock valued at $87,617,000 after buying an additional 8,903 shares during the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of Blueprint Medicines Corporation by 68.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,410 shares of the biotechnology company’s stock worth $173,000 after purchasing an additional 1,391 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of Blueprint Medicines Corporation by 43.9% during the 2nd quarter. California State Teachers Retirement System now owns 68,861 shares of the biotechnology company’s stock worth $3,489,000 after purchasing an additional 20,999 shares in the last quarter. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Blueprint Medicines Corporation during the 2nd quarter worth $525,000. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Blueprint Medicines Corporation by 79.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 29,862 shares of the biotechnology company’s stock worth $1,513,000 after purchasing an additional 13,194 shares in the last quarter. 90.71% of the stock is currently owned by institutional investors and hedge funds.

Blueprint Medicines Corporation Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Analyst Recommendations for Blueprint Medicines Corporation (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.